ANTIHISTAMINE META-ANALYSIS "LEGITIMATELY ANALYZES" DRUG EFFICACY DATA as a single, multi-center study on the use of antihistamines in the common cold, Nonprescription Drugs Advisory Committee member Marcus Reidenberg, MD, Cornell Medical Center, observed at a Nov. 15 joint meeting of NDAC and the Pulmonary- Allergy Drugs Advisory Committee. Noting that much of the data analyzed alone showed inconsistent associations between antihistamines and cold symptom improvement, Reidenberg said, the combined analysis demonstrated "the drag was different from placebo by more than a reasonable likelihood that it was fortuitous."
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
European health systems already pay far too much for new medicines and payers will not accept higher prices to compensate for lower US prices, according to Anja Schiel, from NOMA, the Norwegian health technology assessment body.
In a somewhat surprising move, President Trump’s Federal Trade Commission is continuing a crusade to delist improper listings from the FDA’s Orange Book. Law firm Polsinelli’s chair Chad Landmon discussed the impact of the move on the generic drug industry.
Cell and gene therapy developers may not have to contend with HHS Secretary Robert F. Kennedy Jr.’s animosity like the traditional pharma industry, but his disinterest in distinguishing between the good and bad actors in the space could backfire.
